The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant efficacy in clinical trials for treating obesity. Unlike some available weight loss approaches, retatrutide appears to provide a greater substantial reduction in body size and benefit metabolic markers, p